ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3113

Evaluation of a Clinical Transition Pathway for Adolescents with Autoimmune Diseases

Margot Walter1, Sylvia S.M. Kamphuis2,3, Philomine A. van Pelt4, A. Vroed de5 and Johanna M.W. Hazes6, 1Rheumatology, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 2Erasmus Medical Center, Rotterdam, Netherlands, 3Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Centre, Rotterdam, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands, 5ErasmusMC, Rotterdam, Netherlands, 6Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: evaluation and pediatrics, Transition

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 16, 2016

Title: ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: It is clear that young people (YP) with an autoimmune disease need a transitional process before they are transferred to the adult clinic. Therefore, a clinical transition pathway was implemented in 2009.  Purpose of this transition pathway was to improve transition with provision of care developmentally appropriate, focus on achievement of self-management skills and supporting parents. The aims of this study were I) to evaluate the effectiveness of this clinical transition  pathway, II) to evaluate the experiences and satisfaction in YA with autoimmune diseases in the transitional process.

Methods: All YP with an autoimmune disease who have been transferred from the pediatric to the adult rheumatology between 2009-2015 via the clinical transition pathway, were enrolled in this study. Most important points are an early start (14 years) with focus on self-management skills and independency using an individual transition plan (ITP) for each patient, joint consultations with professionals from pediatric and adult rheumatology and supporting parents in letting go. The ITP, a tool for  developing self-management skills is essential in this pathway.   Outcome measures for effective transition were drop out of care and completed ITP. To evaluate  effectiveness electronic patients records(EPR) (n=158) were reviewed on completed ITP’s and drop out of care. Additionally YA were asked to complete questionnaires after transition for the experience and satisfaction. Satisfaction with transition was measured with a transfer experiences scale, the OYOF-TES¹ (range 18-90) and a VAS scale (range 0-10); higher scores indicating higher satisfaction. Self-efficacy as an important variable for measuring self-management behavior was evaluated with the OYOF-SES² (range17-68, higher score, more SE).

Results: 158 YP were asked to participate, 77 YP returned questionnaires, a response rate of 50%. No difference was found between responders and non-responders on demographics and disease activity. Of 158 YA who ran through the clinical pathway, the overall rate of drop out was only 3.2% after one year. Of all YA 75% were transferred with an ITP. Satisfaction with transition measured with the OYOF-TES was high, 73.45 (SD 13.07). The VAS satisfaction was high with a mean of 7.6 (SD 1.62). Topics important for adolescents were discussed in almost all YA (96%). The OYOF-SES  58.65 (SD4.52). 

Conclusion: The implementation of a  clinical transition pathway was successful, a low dropout rate was seen and YP were satisfied with the transition process. High levels on the self-efficacy scale were reported, suggesting confidence of YP to achieve enough self-management skills. ¹ van Staa A, Sattoe JN Young adults’ experiences and satisfaction with the transfer of care.     J Adolesc Health. 2014 Dec;55(6):796-803. doi: 10.1016/j.jadohealth.2014.06.008. Epub 2014 Aug 19. ²A.L. van Staa, H.A. van der Stege, S. Jedeloo, et al. Readiness to transfer to adult care of adolescents with chronic conditions: Exploration of associated factors. J Adolesc Health, 48 (2011), pp. 295–302  


Disclosure: M. Walter, None; S. S. M. Kamphuis, None; P. A. van Pelt, None; A. Vroed de, None; J. M. W. Hazes, None.

To cite this abstract in AMA style:

Walter M, Kamphuis SSM, van Pelt PA, Vroed de A, Hazes JMW. Evaluation of a Clinical Transition Pathway for Adolescents with Autoimmune Diseases [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-a-clinical-transition-pathway-for-adolescents-with-autoimmune-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-a-clinical-transition-pathway-for-adolescents-with-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology